Compare FTCI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | CGTX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 102.9M |
| IPO Year | 2021 | 2021 |
| Metric | FTCI | CGTX |
|---|---|---|
| Price | $3.85 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $10.80 | $3.33 |
| AVG Volume (30 Days) | 106.5K | ★ 2.6M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $45.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $3.21 | $0.55 |
| 52 Week High | $12.75 | $3.83 |
| Indicator | FTCI | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.71 | 38.85 |
| Support Level | $3.30 | $0.55 |
| Resistance Level | $5.40 | $1.19 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 6.70 | 14.80 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).